Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: Effect of treatment

Journal of Rheumatology

Volumn 37, Issue 4, 2010, Pages 711-716

  Foster, Will ^a   Carruthers, David ^b   Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Endothelium; Laser doppler; Macrovascular function; Microvascular function; Rheumatoid arthritis; Von Willebrand factor

Indexed keywords

ACETYLCHOLINE; ADALIMUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOREARM; HUMAN; HYPERTENSION; INFLAMMATION; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; PULSATILE FLOW; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 77950682947     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090699     Document Type: Article

References (25)

1. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-2745 (Pubitemid 34016192)
2. Blann AD. Viewpoint: endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 2000;11:623-630
3. Rothschild BM, Masi AT. Pathogenesis of rheumatoid arthritis: a vascular hypothesis. Arthritis Rheum 1982;12:11-31.
4. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95:49-55.
5. Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008;35:398-406. (Pubitemid 351374411)
6. Wallberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapää-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008;37:1-5.
7. Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;48:72-80. (Pubitemid 36091650)
8. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995;38:1337-1344
9. Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007;192:391-395 (Pubitemid 46726319)
10. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology 2008;47:1780-1784
11. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al; ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. J Hum Hypertens 2001;15 Suppl 1:S11-2.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
13. Short PE, Williams CE, Picken AM, Hill FGH. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci 1982;39:351-355 (Pubitemid 12001395)
14. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115
15. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen levels in connective tissue disorders. Ann Clin Biochem 1992;29:67-71.
16. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-3078
17. Daza L, Aguirre M, Jimenez M, Herrera R, Bollain JJ. Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 2007;26:533-537 (Pubitemid 46359293)
18. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977;1:195-197
19. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol 1991;50:320-322
20. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Mäkimattila S, Taskinen MR, Yki-Järvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002;22:1637-1641
21. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-2187 (Pubitemid 35222210)
22. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes. A comparative study. Arterioscler Thromb Vasc Biol 2009;29:1702-1708
23. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood groups and the incidence of ischaemic heart disease. Br J Haematol 1994;88:601-607 (Pubitemid 24345110)
24. Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000;102:1470-1472
25. Raza K, Carruthers DM, Stevens R, Filer AD, Townend JN, Bacon PA. Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis 2006;65:946-948